LABT Latest Headlines

Lakewood-Amedex’s Nu-3 Achieves Key Milestones Ahead of Phase 2 Trials for Diabetic Foot Ulcers

Market Chameleon (Mon, 18-May 8:35 AM)

LABT’s Nu-3 Shows Near-Zero Resistance Development—Major AMR Breakthrough for Diabetic Foot Ulcers

Market Chameleon (Fri, 1-May 10:30 AM)

LABT’s Nu-3 Shows Low Resistance Development Compared to Standard Antibiotics—A Potential Game-Changer for Diabetic Foot Infections

Market Chameleon (Fri, 1-May 8:59 AM)

Lakewood-Amedex Biotherapeutics Lists on Nasdaq: Spotlight on Novel Antimicrobials and Diabetic Foot Ulcer Opportunity

Market Chameleon (Fri, 24-Apr 7:05 AM)